Physicians' Academy for Cardiovascular Education

Anticoagulation 2017: The key lessons and implications from RE-CIRCUIT / RE-DUAL

Latest frontiers in anticoagulation therapy (1/4)

Jan. 12, 2018 - Prof. John Eikelboom, prof. Saskia Middeldorp, Dr. Hanna Pohjantähti-Maaroos

Prof. John Eikelboom summarizes results from RE-CIRCUIT / RE-DUAL PCI trials and discusses the implications for clinical practice.


Show transscript

Video navigation menu

  • RE-CIRCUIT: Uninterrupted dabigatran versus warfarin for ablation in AF 01:19
  • RE-DUAL PCI: Dual antithrombotic therapy with dabigatran after PCI in AF 03:38
  • Should patients on factor Xa inhibitors be switched to dabigatran before catheter ablation? 06:08
  • Will RE-DUAL PCI data change clinical practice? 07:57
  • How do the RE-DUAL results compare with triple therapy? 09:27
  • Can RE-DUAL PCI data also be applied to patients treated with ticagrelor? 10:48
  • Do these results apply to patients on hemodialysis? 13:00

Educational information

This educational video is part of a series called 'Latest frontiers in anticoagulation therapy'.

Educational objective:

To review and summarize recent clinical evidence on non-vitamin K antagonist anticoagulants (NOACS) in patients with atrial fibrillation and thrombosis

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.



Prof. John Eikelboom, Associate Professor in the Department of Medicine at McMaster University, Hamilton, Ontario, Canada


Prof. Saskia Middeldorp, internist, professor of Vascular Medicine at the Academic Medical Center Amsterdam, The Netherlands

Dr. Hanna Pohjantähti-Maaroos, Heart Center, Kuopio University Hospital, Finland


Funding to produce this educational video series was provided by an unrestricted educational grant from Boehringer Ingelheim.

View the slides of this presentation